Modality
Radioligand
MOA
TYK2i
Target
GIP-R
Pathway
NF-κB
T2DEoE
Development Pipeline
Preclinical
~Jan 2010
→ ~Apr 2011
Phase 1
~Jul 2011
→ ~Oct 2012
Phase 2
~Jan 2013
→ ~Apr 2014
Phase 3
~Jul 2014
→ ~Oct 2015
NDA/BLA
~Jan 2016
→ ~Apr 2017
Approved
Jul 2017
→ Nov 2028
ApprovedCurrent
NCT06667298
1,362 pts·EoE
2017-07→TBD·Active
NCT05383343
2,529 pts·T2D
2019-10→2028-09·Not yet recruiting
NCT03620201
1,599 pts·T2D
2019-10→2028-11·Completed
5,490 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2028-09-192.5y awayPh3 Readout· T2D
2028-11-142.6y awayPh3 Readout· T2D
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Active
Approved
Not yet…
Approved
Complet…
Catalysts
Ph3 Readout
2028-09-19 · 2.5y away
T2D
Ph3 Readout
2028-11-14 · 2.6y away
T2D
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06667298 | Approved | EoE | Active | 1362 | SeizFreq |
| NCT05383343 | Approved | T2D | Not yet recr... | 2529 | UPCR |
| NCT03620201 | Approved | T2D | Completed | 1599 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 |